GVB Biopharma Acquisition

A TRANSFORMATIONAL ACQUISITION The acquisition of GVB allows 22nd Century to leverage its expertise in receptor and plant science to develop its hemp/cannabis franchise and add significant scale in the immediate-term Market Leadership in Hemp- Derived Products Compelling Financial Impact Key Strategic Benefits and Synergies 22ND CENTURY GROUP ▪ GVB is widely regarded as a best-in-class operator with an estimated 15% share of the hemp-derived active ingredients market ▪ Control from biomass to ingredients to finished goods ensuring attractive prices, quality, purity (99%+ isolates) and traceability ▪ cGMP and NSF-audited facility ■ Significantly increases 22nd Century's revenue and accelerates the path to profitability Immediately accretive to top and bottom line Manageable working capital investments and limited capital expenditure requirements to drive significant growth ▪ GVB's production and formulation capabilities are uniquely suited to leverage and monetize 22nd Century's IP portfolio and research capabilities ■ ▪ Crop developments by 22nd Century will lead to dramatic margin expansion for GVB sales ▪ Manufacturing capabilities for various form factors represent an under-penetrated growth opportunity that 22nd Century leadership is well-qualified to capitalize on Deepens global footprint in geographic markets targeted for growth 4

View entire presentation